Jubilant Ingrevia Limited (JUBLINGREA) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹586.95 (-0.41% day change)
Key ratios
- P/E ratio
- 33.37
- P/B ratio
- 2.75
- ROE (%)
- 8.89
- ROCE (%)
- 10.06
- Debt/Equity
- 0.25
- Dividend yield (%)
- 0.92
- Market cap (₹ Cr)
- 9,257.17
Forensic checks
Piotroski F-Score: 7/9 · Altman Z-Score: 6.64 · Beneish M-Score: -2.27
InvestSights quality score
63.3/100 — Above Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- Lean annualised savings: guided 120Cr, delivered 120Cr (FY26) — met guidance
- Total capex: guided 600Cr, delivered 109Cr (H1 FY26) — missed guidance
Latest earnings call (Q2 FY27)
AI summary: The most important signal is that Jubilant Ingrevia’s FY27 earnings confidence is broadening beyond the uncertain large CDMO contract. Management retained EBITDA guidance of ₹750 crore-₹800 crore and expects to be closer to the upper end, while the confirmed pipeline excluding the large contract has peak potential of ₹1,500 crore-plus, with at least one-third expected this…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.